All the Active Ingredient Drugs
Interleukin Inhibitor, Monoclonal Antibody. Mirikizumab 100 mg/ml. Pre-filled syr./pen with sol. for SC inj. 2X 100 mg/ml and 200 mg/2 ml
Induction dose: 300 mg by IV inf. for at least 30 minutes at weeks 0, 4 and 8.
Maint. dose: 200 mg (i.e. two pre-filled syringes or two pre-filled pens) by SC inject. every 4 weeks after induction.
Tmt of adults with moder. to sev. active ulcerative colitis who have had an inadeq. response with, lost response to, or were intol. to either convent. ther. or a biologic tmt.
Tmt. of adults with moder. to sever. active Crohn's dis. who have had an inadeq. response with, lost response to, or were intol. to either conventional ther. or a biologic tmt.
C/I: Hypersens. Clin. important active infect. (active TB).
Interleukin Inhibitor, Monoclonal Antibody. Mirikizumab 20 mg/ml. VIAL , conc. for sol. for inf. 1 X. 300 mg/15 ml
Induction dose: 300 mg by IV inf. for at least 30 minutes at weeks 0, 4 and 8.
Maint. dose: 200 mg (i.e. two pre-filled syringes with 100 mg each or two pre-filled pens) by SC inject. every 4 weeks after induction
Tmt of adults with moder. to sev. active ulcerative colitis who have had an inadeq. response with, lost response to, or were intol. to either convent. ther. or a biologic tmt. Tmt. of adults with moder. to sever. active Crohn's dis.
who have had an inadeq. response with, lost response to, or were intol. to either conventional ther. or a biologic tmt.
C/I: Hypersens. Clinic, important active infect. (active TB).
